Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 5
Submit an article Journal homepage
53
Views
13
CrossRef citations to date
0
Altmetric
Review

Costs of multiple myeloma and associated skeletal-related events in The Netherlands

Martijn T Groot Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Room L3-105, PO Box 1738, 3000 DR Rotterdam, The Netherlands. [email protected]
,
Peter C Huijgens VU University Medical Center, Department of Hematology, Amsterdam, PO Box 7057, 1007MB Amsterdam, The Netherlands. [email protected]
,
Pierre J Wijermans Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Room L3-105, PO Box 1738, 3000 DR Rotterdam, The Netherlands. [email protected]
&
Carin A Uyl-de Groot Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Room L3-105, PO Box 1738, 3000 DR Rotterdam, The Netherlands. [email protected]
Pages 565-572 | Published online: 09 Jan 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Debajyoti Bhowmik, Dionne M. Hines, Michele Intorcia & Rolin L. Wade. (2018) Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. Journal of Medical Economics 21:6, pages 622-628.
Read now
Emily Nash Smyth, Ilaria Conti, James E. Wooldridge, Lee Bowman, Li Li, David R. Nelson & Daniel E. Ball. (2016) Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. Journal of Medical Economics 19:5, pages 477-486.
Read now
J.A. Carter, A. Joshi, S. Kaura & M.F. Botteman. (2011) Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. Journal of Medical Economics 14:3, pages 288-298.
Read now

Articles from other publishers (10)

Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham H. Jackson & Gordon Cook. (2023) Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic. Blood Cancer Journal 13:1.
Crossref
Sikander Ailawadhi, Rohan Medhekar, Nicole Princic, Robert Fowler, Oth Tran, Debajyoti Bhowmik & Sumeet Panjabi. (2019) Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. Journal of Oncology Pharmacy Practice 26:5, pages 1070-1079.
Crossref
Maria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, Rita Rizzi, Alessandro Gozzetti, Patrizia Falco, Carlo Lazzaro, Elisa Martelli, Mario Boccadoro, Francesco Lauria, Vincenzo Liso, Michele Cavo & Robert Foa. (2018) Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. Tumori Journal 99:4, pages e193-e202.
Crossref
Avani D. Joshi, John A. Carter, Marc F. Botteman & Satyin Kaura. (2011) Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clinical Therapeutics 33:3, pages 291-304.e8.
Crossref
Evangelos Terpos, Meletios A. Dimopoulos & James Berenson. (2011) Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical Reviews in Oncology/Hematology 77, pages S13-S23.
Crossref
James R. Berenson. (2010) Therapeutic Options in the Management of Myeloma Bone Disease. Seminars in Oncology 37, pages S20-S29.
Crossref
Ramón García-Sanz, Adrián Alegre, Francisco Javier Capote, José Mariano Hernández, Laura Rosiñol, Javier de la Rubia, Anna Sureda, Felipe de Arriba, Joan Bargay, Joaquín Díaz Mediavilla, José García-Laraña, Juan José Lahuerta, María Victoria Mateos, Felipe Prósper, Jesús San Miguel & Joan Bladé. (2010) Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología. Medicina Clínica 134:6, pages 268-278.
Crossref
Kate McKeage & Greg L Plosker. (2008) Zoledronic Acid. PharmacoEconomics 26:3, pages 251-268.
Crossref
M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman & M. Aapro. (2006) Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Annals of Oncology 17:7, pages 1072-1082.
Crossref
Fred Saad. (2005) Zoledronic acid: past, present and future roles in cancer treatment. Future Oncology 1:2, pages 149-159.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.